TY - JOUR T1 - Feasibility of Concomitant Chemoradiotherapy in Daily Practice for Patients with NSCLC Stage III JF - Anticancer Research JO - Anticancer Res SP - 4673 LP - 4676 VL - 36 IS - 9 AU - FEMKE S. VAN DER MEER AU - FRANZ M.N.H SCHRAMEL AU - MARCO VAN VULPEN AU - SHERIF Y. EL SHAROUNI Y1 - 2016/09/01 UR - http://ar.iiarjournals.org/content/36/9/4673.abstract N2 - Background: In patients with non-small cell lung cancer (NSCLC), approximately 25% have locally advanced disease. For patients with irresectable (N2-3 or T4) or inoperable disease, treatment consists of chemoradiotherapy. Concomitant chemoradiotherapy improves survival compared to sequential chemoradiotherapy in these patients. Patients and Methods: Treatment plans and completion of treatment was evaluated for all patients treated at the St. Antonius Hospital from 2008-2011 for NSCLC stage IIIA/B not eligible for surgery. Results: Between 2008 and 2011, 180 patients with NSCLC stage III were treated at our hospital. A total of 152 patients were not eligible for surgery; in 78 (51%) patients, primary treatment was chemoradiotherapy; 31 (20%) were planned for concomitant treatment. The most frequent reasons for refraining from concomitant chemoradiotherapy were limitations of radiotherapy constraints and condition of the patients (87%). Conclusion: Although concomitant chemoradiotherapy is the standard-of-care in patients with stage IIIA/B NSCLC ineligible for surgery, the majority (80%) of the patients were treated otherwise. ER -